Vaxxinity, Inc. (VAXX)
OTCMKTS · Delayed Price · Currency is USD
0.0010
-0.0420 (-97.67%)
Sep 12, 2025, 10:21 AM EDT
Vaxxinity Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
126.75K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 66.00K | -491.00K | -88.15% |
| Dec 31, 2020 | 557.00K | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| AMJ Global Technology | 39.00 |
Vaxxinity News
- 1 year ago - Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - GlobeNewsWire
- 1 year ago - Vaxxinity Issues Shareholder Letter - GlobeNewsWire
- 1 year ago - Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - GlobeNewsWire
- 1 year ago - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 1 year ago - Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 1 year ago - Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 - GlobeNewsWire
- 1 year ago - Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewsWire
- 1 year ago - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewsWire